Review Article
Apathy in Alzheimer’s Disease: Any Effective Treatment?
Table 2
Characteristics and outcome of clinical trials using monoaminergic compounds on apathy in Alzheimer’s disease.
| Study | Study design | Sample size | Intervention | Time | Apathy as a primary or secondary objective | Apathy assessment instrument | Outcome |
|
Herrmann et al., 2008 [22] | Randomized, double blind, placebo-controlled crossover | 13 | Methylphenidate (5–10 mg/day) | 2 weeks | Primary | Apathy Evaluation Scale (AES) | Greater reduction in AES score with methylphenidate than placebo () |
| Frakey et al., 2012 [23] | Randomized, placebo-controlled | 23 | Modafinil (200 mg/day) | 8 weeks | Primary | Frontal Systems Behavior Scale (FrSBe) | No significant improvement in apathy |
| Padala et al., 2010 [24] |
Open-label | 23 | Methylphenidate (10 mg/day) | 12 weeks | Secondary | AES | No significant improvement in apathy |
|
|